Serum soluble RAGE levels and carotid atherosclerosis: the Northern Manhattan Study (NOMAS).
BACKGROUND
Recent cohort studies suggested that serum levels of soluble Receptor for Advanced Glycation End-products (sRAGE) are associated with the risk of cardiovascular disease. We hypothesized that sRAGE levels are associated with subclinical atherosclerosis in a racially and ethnically diverse population.


RESULTS
828 stroke-free participants from the Northern Manhattan Study (mean age 71.1±8.7yrs; 64% Hispanic, 19% black, and 17% white) underwent high-resolution carotid B-mode ultrasound to measure carotid plaque (present in 62% of subjects) and intima-media thickness (IMT) (mean Total=0.96±0.10 mm). Serum sRAGE was measured by ELISA and associations tested between sRAGE with IMT and plaque presence. Soluble RAGE levels were not associated with plaque presence or IMT after adjusting for sociodemographic, vascular risk factors and medication use. Stratification by race-ethnicity did not reveal any associations with carotid IMT or plaque.


CONCLUSIONS
In the present study, sRAGE levels were not associated with carotid atherosclerosis.
Division of Endocrinology, Diabetes & Metabolism, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Barry I
BI
Hudson
Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Hannah
H
Gardener
Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Wen
W
Liu-Mares
Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Chuanhui
C
Dong
Department of Biostatistics, Mailman Public School of Health, Columbia University, New York, NY, USA.
Ken
K
Cheung
Stroke Division, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, USA; Department of Epidemiology, Mailman Public School of Health, Columbia University, New York, NY, USA.
Mitchell S V
MS
Elkind
Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Neuroscience Program, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Clinton B
CB
Wright
Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Evelyn F. McKnight Brain Institute, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Ralph L
RL
Sacco
Department of Neurology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA; Department of Epidemiology and Public Health, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, USA.
Tatjana
T
Rundek
D001741:Black or African American; D015415:Biomarkers / Q000097:blood; D002340:Carotid Artery Diseases / Q000097:blood* / Q000175:diagnosis / Q000208:ethnology; D059168:Carotid Intima-Media Thickness; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006630:Hispanic or Latino; D006801:Humans; D008297:Male; D009519:New York City / Q000453:epidemiology; D058226:Plaque, Atherosclerotic; D000067759:Receptor for Advanced Glycation End Products / Q000097:blood*; D012307:Risk Factors; D044465:White People
C000593871:AGER protein, human; D015415:Biomarkers; D000067759:Receptor for Advanced Glycation End Products
Atherosclerosis; Biological marker; Carotid ultrasound; Hispanics; IMT; Plaque; RAGE (receptor for advanced glycation end products)